Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still up 60 cents for the day of about 12 percent increase. The property there may be littered with gold. When they were constructing and digging to build the road for trucks to the property, they found gold.
Don't think there are enough retail investors still interested for the amounts needed. Another small company, ACTC, which was running out of money awhile ago, found a Korean firm to take a major position with investment. Maybe some rich old lady who is a pet lover? It be interesting to know if there are some people they have already identified as potential investor(s).
You say you don't have any position long nor short, an associated with other investment entities, not a pay basher nor pumper, then why do you spend so much time on this technology? Just a hobby?
Questions. Who or what is Smithline? Is it a person or a company? If it forecloses and there are no buyers, what is it going to do with a handful of RECAF patents? TIA.
Gold, you are not a doctor, right? You are definitely not an oncologist nor a urologist, right? Have you carefully read Moro's paper and BOCX releases? If you read it again, RECAF is in everybody at low levels. Moro's paper does not say why, but I would guess some stem cells produces RECAF, as some stem cells are probably still close to fetal cells. There may be left over fetal cells in the adult body according to some theory. The so call "positive" threshold level is adjusted to trade off sensitivity against false positives. Just detecting RECAF is not meaningful, as there are a some small levels of RECAF in almost everybody. IMO, by using personalization and velocity calculations, the threshold value can be compensated depending on the individual's circumstances like the case of 70 year old people. From my own limited experience, people get hit by life threaten lung cancers usually around the 70 year point, so that will kill them if they survive slow prostate malignancy. It is similar to the temperature gauge in a car (for those cars with more than just the warning light) that on a cool day if the gauge points high, it usually means there is a leak in the radiator hose that should be checked for, but on a very hot day the same high gauge reading is normal. The gauge has to be read with the circumstances in mind, and the gauge cannot be read just blindly without thinking.
Not too many years ago, doctors and the medical field tell people to check for cancer signs themselves, as medical diagnostics for cancer were not as well developed as today. The medical establishment use to show pictures of how women should check for lumps, and how people should be on the look out for signs like chronic coughing. Medicine do more diagnostics now like colonoscopy, mammograms and the like, but medicine still has severe limits on how effective that can catch cancer early. A lot of it has to deal with costs like insurance companies are not going to pay for PET Scans which can catch almost all types of solid cancers at better than pea size. In view that it is still ultimately up to the individual to monitor for cancer, the medical establishment should allow the individual to use diagnostics themselves. The FDA should lay off, unless it can promise to be able to do it all in checking for cancer.
No sweat no gain. They can only sell stocks for so long as the stock price going ever lower near zero. They have to decide whether they are just going to remain a research outfit forever, or they are going to be a real business. Real businesses do a lot of selling besides stocks. Like Edison said, innovation is ninety-nine percent sweat. The same can be said about doing business that it is ninety percent selling (and not just selling more stocks.)
I don't think that the permit consultant is mucking around, specially with Hothchild as a major holder.
If there is unusual stock price movements, that should tell a lot. I rather that a heads up is given even if it is unconfirmed. This way insiders and market makers would not have a period of knowing something that outsiders don't. Late yesterday, I added on dip. Did market makers knew something already yesterday before the market closed?
Perhaps Moro should hire selling trainers to give selling training seminars to all at BOCX. Start with in house practice selling, and progressing to actual selling in the real world initially with the trainer at the side, and then solo selling. Sort of like learning to fly an airplane: practice on the ground, flying with trainer by the side, and finally soloing.
Canadians don't get cancer? Why BOCX don't try to sell human cancer tests in Canada? ROSG just announced selling of their diagnostics, which are fair expensive microRNA based, in Canada:
http://finance.yahoo.com/news/Rosetta-Genomics-and-Warnex-bw-1091655770.html?x=0&.v=2
If it is a single buyer of 150M shares, then it will buying a super majority position. Penny stock ACTC had a recent Korean company buying like that. Do you think that may be a possibility?
The medical profession without trying it for real runs the risk of not being fully correct in downplaying the benefits for early detection while up playing the possibilities of wasting money on none beneficial new technologies. Does it sound like the insurance companies trying to save money and increase profits for the insurance companies themselves? Most new technologies have to be fine tuned through a period of usage to optimize they effectiveness while to minimize inappropriate areas of use. It is hard of anybody including doctors to just sit around and come up with the refinements without actually using the new technologies. Plus, there is a lot of politics in medicine as big pharma, insurance companies, political parties, and even religious groups are trying to advance their own agendas, which may not be in the best interest of the people. Look at the news on health reform and see how political medicine has become. The fact is that about half a million people in the US alone died of cancer every year. Cancer is starting to over take heart disease as the number one killer in the US. Any body, except those with agendas, will agree that medical improvements are needed for detecting and treating cancer.
These sell first and get the money companies like Microsoft, IBM and Sloan's GM are big money makers (was in the case of GM) even though some techies say that their products are not of the best technically. Sloan in his classic book said it the best. He basically said that if left to the engineers and techies, they will make change after change delaying things until his company goes out of business. There is a point of diminishing returns according to economic theory where technical people ignore in their habit of "playing" with technologies, which they are familiar with disregarding other as important, if not more important, needs such as selling to generate some revenue.
As a salesman, my aim is to get your credit card number, or paypal payment first. I let the technical people worry about the rest, even if they have to work nights to fulfill the order. In sales oriented companies, marketing does not wait on techies. Get the money first, and let the techies worry later is the motto. Sloan long time ago wrote in his classic business book "My Years at General Motors" to not to wait on his chief engineer Kettering to make change after change on the new air cooled car design, but to sell what they had. If Sloan waited for the air cool engine to be perfected, he would had waited over thirty years before the air cooled cars like the Beetle finally made it to the road but only for a relatively short period. Sell and let the techies worry later.
Big pharmas are in general not entrepreneurs "rushing" to pioneer new technologies. People in big companies spend almost all of their time on their existing businesses. Big companies pass up a lot of new technologies in the past that were blockbusters. For example, IBM rejected Chester Carlson's pitch for a new copying machine technology once. Big companies rather buy up technologies from small companies after the small companies have pioneered the market and after the small companies have made actual significant revenue from selling. That is why many small companies just do their own marketing first. For example, ROSG (Rosetta Genomics) is manufacturing its own diagnostics and selling direct, although it also licensed large pharma in its base country to sell the diagnostics. To know exactly why Abbott and Inveness have not already put BOCX diagnostics in doctor offices and drug stores, one has to ask (twice according to MacArthur the great salesman, as people will give a phony polite answer the first time they are asked, and they need to be asked a second time at least before they will give a truthful answer) these companies. I would think that if BOCX does a pilot selling project to demonstrate what the extend of market reception to pet diagnostics, big pharmas and big labs will have some more concrete data to base their decisions on. The big companies have many ongoing work and projects, and they are not just sitting around waiting for pet diagnostics to show up so that they can jump on the pet diagnostics. Big company executives usually have to go through a lot of paper work before making any decision on new projects to protect their jobs and to prevent their shareholders from complaining. They usually spend a lot more time dealing with their existing businesses rather than pioneering new things. It is call inertia. The bigger the company the bigger the inertia. Nothing unusual.
I am not sure cancer diagnostics need FDA approval for human use. I know that ROSG (Rosetta Genomics) is selling its cancer diagnostics (using fairly expensive microRNA technology) with only NY State approvals. See below link to InvestorHub post:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=30872395
I tend to agree with you that Inveness is not progressing, as I don't see any RECAF "test sticks" in the local drug store, nor at my doctor's office. If it is going to be sold, these test sticks should by now be in stores or doctor's offices. The original sales pitch from BOCX's hired stock "analyst" publications imply that BOCX was going to sell these test sticks like pregnancy test sticks. The implication was that BOCX was going to make these sticks (as the sticks were simple to make) and sell them. However, in reality, BOCX's business plan seems to be just licensing out its technology, as its people are going to remain academic type of researchers. Maybe I misread the pitch, which I obviously did to assume that BOCX is going into direct manufacturing and marketing instead of going into just a licensing business. In view of the confusion of just what BOCX business plans are, it needs to be first clarified with the pet program whether BOCX intends to market it itself or whether it is going to be another licensing program. So far, the licensing approach has not generate any revenue. So far, BOCX has not appear to have initiated any direct marketing program as it waits for the licensing programs to work themselves out. It is clear that BOCX cannot hold its breath for much longer waiting for the licensing approach to work. The only alternative remaining, IMO, is to give direct marketing a serious try. I have a friend in the dog grooming business. People who have their dogs groomed obviously are willing to spend money on their dogs. Dog groomers probably know the dogs they groom on a regular basis better in some way than the vets as they spend more time with the dogs and their owners. A quick market survey can be done calling on vets and even talking to dog owner walking their dogs on the street. IMO, the test should be sold similar cholesterol monitoring as a general health monitoring program, in additional to specifically a onetime cancer test. All dogs (and people) should have a base line established while they are healthy and just entering middle age. By subsequent test monitoring, unusual changes and increases indicate increasing risks. Of course, high initial test result imply problems already is occurring.
If they give me a distributorship, I will besides mailing out flyers and calling on vets: work with dog glooming shops, pet stores, Ebay dog products section, dog walkers, Internet blogs, facebook type Internet sites, dog owner mailing lists and the like. The company will have to do its part getting the word out too, of course, but this thread is questioning the ease of doing "cold calls" on dog owners. It is hard work, specially to pioneer new products, but even big pharma send out salespeople to call on doctors directly. A company that learns to sell direct, instead on depending solely on big pharma to do the selling for them, will always have the advantage of maintaining its independence and not depending on the whims of another company. When IBM adopted Microsoft's DOS as the default operating system for the original IBM PC, Microsoft got an instant leg up to become a major player. Later in the mist of a joint development of OS2, IBM and Microsoft separated and became competitors for the follow on operating system for new PC's. IBM went on with OS2 by itself, while Microsoft went on with Windows. Gates being experienced in direct selling was able to beat out once partner IBM. Windows became the established operating system, while OS2 is never heard of since.
Here is the link to ROSG's NY State approval for selling direct:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=30872395
Why not sell direct to humans once they practice up on selling direct to vets and dog owners? ROSG started selling their cancer diagnostics once it got NY State approval, and it did not need FDA approval. See ROSG postings on InvestorHub around the second half of 2008. Not sure what Canadian regulations are concerning diagnostics. Does Canada have an FDA equivalent?
Huge sales effort may or may not require a lot of money depending on how it is done. Traditional marketing can be expensive. On a shoe string, early Microsoft had student Gates flew around the country selling to Altair, Radio Shack and IBM not needing much money. BOCX's burn rate is relatively large for its size. Yes, these early biotechs are risky speculations. Dilutions are heavy for early investors in biotechs. Wonder who they are going to raise money from.
Some insurance companies may be a horses of different colors. They may not like to pay for another test, and possible extra testing resulting in false positives.
While I agree that doctors may have to go through a learning curve to pin down how it can be effectively used, and many people in general hate to learn new things, I could think of situations where doctors could love it. For example, for years my doctor had been after me to do a colonoscopy as I had reached the age when standard medical practice calls for this exam, and for years I had put it off as I like most people had been lax in even getting the standard annual physical. So my doctor would do stool sample cards, and then digital exams and brushing the digital on a stool blood test card to "prove" that there was blood requiring the colonoscopy, but the test card came out negative until last year when the digital exam was performed real "hard" resulting in the test card showing some blood detection, and the doctor made the hard sell that something real bad may be happening in my colon, and I gave in to the colonoscopy exam, which came out without any polyp nor cancer tumor detection. Now with the theoretical positive RECAF test, doctors would just put people through the standard set of exams that most people put off like chest X-rays, colonoscopy, mamogram, check for weight lost, unusual pain, general poor appearances, family history of cancers etc. Most of these standards for checking for cancer already exist as large unexplained weight lost need to rule out cancers, and new standards can be set up by the medical establishment on what tests to make. There are also more specific markers. Full CAT scan is another step. If RECAF Velocity is verified as effective with further research, such calculations can refine the test data interpretation. Currently unexplained heavy weight lost, unexplained coughing, unexplained pain and such would already call for examination for cancer. Nothing unusual about people needing to do physicals that people usually skip. However, it is hard for the medical establishment to adopt new ways whether technically justified or not, IMO. That is the reality. No technology is perfect, but these imperfect technology is used by smartly using them. Just like people waiting for the perfect spouse, they wait forever. If technology needed to be used, the technology has to be used with their imperfections. No big deal. The big deal often is trying to get people and doctors to change.
I agree that there is a place for cancer markers. Like any tool used in a very complex environment of cancers, which come in many variations and situations, there are places and times where it can be used to advantage, and there are times and places where the tool may be used to advantage. However, BOCX is too small to work out all the complexities, which usually are worked out in the world at large anyways. However, as it has been experienced as long ago as in Louis Pasteur's times, the medical establishment is set in its ways and it does not like changes. It appears that BOCX has not been able to pioneer this tool for adoption by the medical field in the past number of years. It may be too small to fully educate the medical field to convince the field to change and adopt the technology. In this severe economic downturn, funds are scarce and the stock markets are at lower levels than during better times. While waiting for some signs of adoption by the medical establishment, BOCX had signaled that it is try to sell in Asia. Recently, it issued a press release about selling to vets and pet testing labs. It is trying to sell directly to none traditional customers. However, it is still trying to sell something new. It is said that only about eight percent of the population are early adopters of new technologies. A lot of hard selling is usually required to pioneer a new product into the market. It is rare that a new type of product will sell itself without much selling effort involved. To announce that it will sell direct is one thing. To demonstrate it has the commitment to put out the necessary selling effort is another. Running out there to potential customers to sell, to close sells and to make money will clearly demonstrate that the technology can make money.
Yea, but cancer is rated by stages 1 to 4. Stage 4 cancer is end stage and most probably untreatable. Stage 3 is severe cancer that is hard to treat but some reasonable chance of being treated. Stages 1 and 2 are fairly small cancers. Most of BOCX releases, if remember correctly, deals with detecting stage 3 and 4 cancers, which are severe enough to be treated or at least monitored closely. About 90% of cancer deaths are caused when the cancer progressed to the stage of spreading via metastasis. In BOCX papers, the lower threshold is adjusted, as there are natural background of RECAF, to trade-off sensitivity versus false positives. IMO, the medical profession has not learned enough to be able to handle small cancers in old people. However, individual common people can still use the data. For example, it is probable that not every very old person will develop the same amount of these small but slow cancers. Some may grow any at all, while some may grow a lot of them. It can be guessed that people who grow a lot of these small cancers may be at a higher risk of one of these small growth turning into a live threatening cancer. A common people who is monitoring markers like RECAF through the years and see the marker level(s) increasing may take lifestyle preventive measures like stopping smoking, eating healthy, avoid too much sun, cured food and the like. The medical establishment is currently not into lifestyle improvement of preventive medicine, while individuals can. Just because a doctor don't prescribe it, doesn't mean that individual shouldn't use it.
Well BOCX bet on the labs and the medical establishment, and not much happened. Now, BOCX plans to sell direct to pet owners and vets, and to Asians. It is a different ball game selling direct. Selling direct means money will come in directly. Selling direct means depending on ones own initiate to go out there and sell, and to go improve selling techniques. It is usually a change for people used to the university environment. Almost anybody can learn to become effective salesmen. It is probably in the genes established by evolutionary necessity. It just needs to be brought out. People walk their dogs everyday on the street. Talk to them and see if they will buy the product.
If you are an older person who your primary doctor will order PSA testing, you probably will notice that the doctor compares your recent PSA scores with your previous PSA testing scores. This is call PSA Velocity. Usually, very high PSA scores coupled with high PSA Velocity (meaning there is a significant increase in PSA levels as compared with previous levels) specially coupled with abnormal digital examination will result in sending you to a specialist. IMO, these tests should be used similarly as with cholesterol testing. High cholesterol test results do not mean your heart is bad and in need of operation or transplant. High cholesterol indicates that the risk of heart and stroke problems is increased. In the same way by getting multiple RECAF (and the like as there are other markers) to build a profile over the years as a person reaches middle age (or if people have family history of early cancers like early breast cancers,) an increase in RECAF "Velocity" may indicate fast growth of cells. As Moro said in his paper, cancer is very hard to detect by the medical profession. Many times, cancer is detected in late stages, which become difficult to impossible to treat. If the velocity of increase of marker(s) is high, this rapid increase usually implies rapid cell growth. Rapid cell growth in a mature person is unusual and probably cancerous. Very high single measurement of marker concentration is most likely bad, specially coupled with other observations like weight lost, pain, unusual organ function, and poor general appearance. Because of malpractice and run away costs, the medical establishment is scared into inaction. However, the common people are not stupid, and they will want easy to use and cheap testing once they learn that doctors are not really good at detecting cancers, until usually it is too late.
OEM versus retail selling is like Microsoft and Apple. Microsoft predominantly is an OEM (Original Equipment Manufacturer) seller as it sells its software to computer system manufacturers like DELL, HPQ and IBM (while IBM was still manufacturing PC's) who in turn sell to the ultimate consumer. This indirect selling is a lot easier as Microsoft only has to sell to only a few dozen PC manufacturers rather having to sell directly to millions of individual customers. Apple is predominantly a retail seller, as it sells basically directly to the ultimate customers. Apple even opened Apple Stores, where it sells directly to customers coming off the street. Both approaches can be successful, although retail selling requires more selling ability, which Jobs is great at. Gates is great at selling too, although his selling ability is effective more with the system manufacturers rather than the folks on the street like his successful selling to Altair Computer, Radio Shack, IBM, Dell, etc. Both Gates and Jobs did a lot for years to pioneer the early pc computer field when it was still a tiny industry, before it was big enough for the large companies to move it like Rado Shack and then, of course, IBM with the IBM PC. Jobs and Gates and other early pioneers had to sell to the end users to build the pc market before the big companies join in. The big companies like IBM did not pioneer the field. The pioneers had to sell directly to the end users, as the big manufacturers were not around in the beginning.
This is somewhat similar to book publishing. Just licensing a book manuscript to a publisher is usually not enough, unless the manuscript is a preordained blockbuster by famous personalities. Usually, after licensing, the author is required to do hard selling of the book by going to television talk shows and the like. It is not like the book publisher will do everything.
IMO, "consumers" in the sense of the common older people on the street would like to use a relatively cheap and easy to use cancer preventive test that works similar to cholesterol monitoring test. But it is hard and time consuming to retail to individual people on the street. OEM selling to "whole sellers" like Abbott is "easier" for a tiny company, but the Abbott are not good at pioneering new products that has limited dollar volume potential. It is probably also related to selling ability. It is not usually enough just to license the technology out to a big outfit and hope that the big outfit will develop the market. It is important to "manage" and to direct the "relationship" by selling the ultimate customer base, which are the doctors that are suppose to order the tests for their patients, and which are the insurance companies that are going to pay for the tests. These customer base are usually set in their old ways, and they have to be sold to make changes. The past is water under the bridge. The future will be largely depend on the ability and on the effort put in selling, IMO. Getting money out of customers these days can be like pulling teeth. But, IMO, common older people will go for easy to use and low cost cancer preventive testing, although a lot of educational and selling effort will be required for direct selling to this customer base. BOCX people just have to get out there and sell, instead of waiting of the existing medical establishment like the doctors, the insurance companies and the testing labs to do something. BOCX needs to review its business plan in view of the past experiences with the medical establishment.
About a year ago more or less, there was, as I remembered, a press release saying something like that Abbott is dropping the license, but BOCX was offering the license for "free" to Abbott but that BOCX can withdraw the offer at anytime unless Abbott expressively renew it. This is a fairly standard thing it appears, as no one else is licensing. Since then I have not kept up with the news much, as I was into some other things. I would imaging that if since then Abbott did not expressively made any action to revere its dropping, there is no real relation there. Whether they can actually pull the pet thing off remains to be seen. It has some potential but it is a low price product area. Success there can build up some scientific justification data for use on humans. ROSG is also in the cancer diagnostics area using microRNA, although its stuff is very expensive, but its stuff do not need FDA approval. ROSG's stuff only need state (in the US) approvals. The era of easy venture capital investment money is no longer as it was in todays harsh economic condition. It is time to get out there and do hard selling.
When Apple Computer started it had only two employees, Jobs and Wosniack to sell its product. As it turned out only one employee, Jobs, was enough to sell, as we all come to know. For an early stage start up during the initial stage of the sales campaign, it is not the dollar amount of sales that is the key, but the growth of sales that is the key. You heard of the term "growth" oriented company? If the company can show that sales are growing exponentially even though the actual revenue amount if still low scale, it can demonstrated the company has the potential to be a "growth" company. When Steve Jobs first started to sell his early Apple computers in stores in his local area, the dollar volume of sales was not tremendous as it was a tiny company initially with tiny number of employees, but the sales growth rate was impressive. A tiny startup is not going to sell millions of units at the start, but it can achieve high growth rates by diligent selling efforts.
It is tough to start up small tech companies, specially small biotech companies, as it is very difficult to determine whether the particular new technology is going to be mature successfully. Thousands of new technologies are developed in the labs every year. But only a few will be really good enough to be successful. There are only a handful of the Bill Gates and Steve Jobs, while there are more Robert's (of Altair computer the first home computer), Osborn's (the first portable PC) and many others not even heard of anymore like the original developers of the spreadsheet Visical, daisywheel printer, Basic interpreter, and even the original IBM PC. The super sized company IBM was knocked out of the PC business after it tried in vein to keep control of the PC by developing the failed PS2. Even with IBM's financial resources and manpower, it failed with the PS2 attempt. Small startups with much limited funds, manpower and sales talent are even more at a handicap. Sales is where most small biotech's have difficulty. The FDA regulations favor big pharma. Doctors, unless they grew up in a family of salesmen, do not have experience in serous selling, as they spend most of their lives in medical schools. But to make money almost always depend of selling. It is rare that people will just hand you the money, specially a large sum of money.
They need to get out at least a couple of hours every day, and make direct face to face sales calls to their customers whether vets, old ladies, dog trainers and just people walking their dogs on the street. Selling is like any other activity where practice makes perfect. Most people, even many great salesmen I have worked with, may be shy about face to face selling, but once they make some successful face to face sales, they will see how easy it can be. Selling is where money is directly made. It can be the most important function of a company. Many companies only have people who have sales experience as CEO's. Providing some free samples can make selling more comfortable for some salesmen, as they feel that they are doing a favor for the customers, rather than just trying to make money off their potential customers. Even big pharmas send out armies of salesmen to call on their customers, and they usually provide free samples; although too much free samples sometimes. Recently, I was at the waiting room of cardiologist office, and a pharm salesperson made a sales call and left over a dozen fairly large boxes of free samples that must work several hundred dollars retail. That is too much free samples IMO to grease the sales call, IMO. Like golf where not every swing, if not most swings, produces intended results, not every sales call goes as desired. But like golf, keeping at it will produce the occasional great result that comes more frequently the more practice is done.
Wonder what the sales campaign looks like for the OncoPet. Long ago, when I just graduated from college, my first job was with the Sales Division at IBM for many years. Of course, IBM had many Fortune 100 companies as customers, but it also sold small products like office typewriters to small businesses. Every so often, we did have a "Cold Call" day, when we just look up the telephone directory, called, and hit the pavement to visit these small businesses. On cold calls, getting a sale on one out of ten visits can be a good day. In normal selling to big companies, most of the effort is educating the customers and supporting them, as computers were fairly new in the old days. One also learned a lot from the customers by interacting with them on sell calls to get ideas on how to use the products in more ways.
Going to your own vet is a great way to start. If you cannot sell to your own vet then the sales approach needs to be improved. Your own vet will tell you the truth. One of the great salesmen McArthur gave the advice to always ask the customer twice for the reason why the customer turned down a sales proposal. He said that the customer will always give a phony polite reason for not buying when asked the first time. Thus, the customer needed to be asked a second time for the real reason for not buying. With the real reason known, McArthur said that then he was able to finally close the sale.
Email response from OncoPet arrived within an hour yesterday, after I posted an inquiry on Investorshub:
Re: Onco-Pet Saturday, August 8, 2009 11:00 PM
From: "Info center" <info@oncopet.net>Add sender to Contacts
To: Rich
Dear Sir: Thank your interest in our company and products. We are setting
up our web site and do not have the material you require at this point, but
will have it in a few more weeks posted in our site. We shall send you the
pertinent information when it is available. Initially the test will be done
at our facilities in British Columbia, Canada and we are working on a
blotting device where you can dry a spot of blood and send it to us for
testing. Until that is ready we'll have to work with serum and test tubes.
We have not decided on a firm price yet. Best regards, the Oncopet team.
On Fri, 24 Jul 2009 05:10:01 -0700 (PDT), Rich
wrote:
> When will the "homebrew" tests for veterinary use be available for order,
> and what is the price? Is it going to be a "test strip" type of test?
> Thank you.
RECAF velocity can minimize false positives, as any exponential increase implies exponential growth of cells, and any exponential growth of cells usually means cancerous growth. False negative is another issue. Are there cancer cell types that do not produce RECAF. Another "universal" cancer marker, telomerase, is not produced in about 10% to 15% of cancer types, which are called ALT-cancers. ALT (Alternate Lengthening of Telomere using DNA recombination rather than telomerase to elongate the telomere) cancer cell types appear to activate the telomere elongation gene program process which is used after the egg cell is fertilized but before the egg is fully established on the womb surface. Before the egg cell is fed energy from the mother via the womb site infrastructure, there is not much energy in the egg to produce telomerase, so more primitive recombination program is used. It may be guessed that in this primitive egg state, RECAF is not yet produced either, so that ALT-cancers probably do not produce RECAF nor telomerase. Fortunately, many ALT-cancer types are relatively treatable, but the telomerase marker will produce false negatives on ALT-cancer types. The Moro paper did not mention whether there are cancer types that do not produce RECAF.
After I bought a few shares a couple of years ago, I emailed Moro using their regular website address about getting a sample to try, and about a search of the NCI database not turning up any hits on RECAF, and the people at NCI inquiry never heard of RECAF. Moro answered back that samples were not available at that time to the public, and that he did not want to tell people at NCI as they might steal the technology. A little weird IMO, as it is patented. Plus the medical profession in general are rather conservative and don't like to try new things, as illustrated by Louis Pasteur's experience of having jam the theory of germs, and to force doctors adopt the simple activity of washing their hands. The medical profession don't like to change or try new things. IMO, Moro should produce test strips cheap for pets and put it on the market. Some pet owners will ask that their vets to build up a historical RECAF profile of their pet dogs that are of breeds that are cancer prone. People might even use it on themselves to construct a profile so as to detect any exponential increases.
PSA Velocity (using two or more PSA test figures to see whether PSA levels are increasing), and PSA Doubling Times (for prostate cancer patients to see how soon the PSA level doubles) are used to fine tune the PSA level interpretation. Are there similar studies of RECAF Velocity and RECAF Doubling Time?
Status of Pet Tests? What is happening to Pet Tests? Are they still working to produce the pet test product? I send an email to the pet test web page address, but get no response at all. Is this a "test strip" implementation for animal hospital or home use?